Minimal and small size invasive breast cancer with no axillary lymph node involvement: the need for tailored adjuvant therapies
Marco Colleoni(European Institute of Oncology), Aron Goldhirsch(Istituti di Ricovero e Cura a Carattere Scientifico), Patrick Maisonneuve(European Institute of Oncology), G. Peruzzotti, Giuseppe Renne, Giulia Viale(Istituti di Ricovero e Cura a Carattere Scientifico), Nicole Rotmensz(European Organisation for Research and Treatment of Cancer), Mattia Intra, Paolo Veronesi(Ripamonti), Chiara Casadio(University of Milan), Rosalba Torrisi(IRCCS Humanitas Research Hospital)
Cited by 76
Related Papers
Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013
|Annals of Oncology|2013|3.7k
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
|Annals of Oncology|2015|1.8k
2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial
|The Lancet|2007|1.5k
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer
|New England Journal of Medicine|2018|1.3k